Volunteering for Clinical Trials Using BCT-100
If you are interested in learning more about the below studies, please visit clinicaltrials.gov for a listing of study locations and their contact information. When you contact a study location, they will ask you some questions to see if you meet the basic criteria required to participate. If you do, they will set up an appointment for a more thorough screening and answer any questions you may have.
| Protocol No. | : | BCT-100-002 |
| Study | : | A phase I dose-escalating study of pegylated recombinant human arginase 1 (PEG-BCT-100) in patients with advanced hepatocellular carcinoma |
| Condition | : | HCC |
| Phase | : | Phase I |
| Study Location | : | Hong Kong |
| Status | : | 
|
| Protocol No. | : | BCT-100-002 Additional Study |
| Study | : | Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 (PEG-BCT-100) treatment in patients with advanced hepatocellular carcinoma |
| Condition | : | HCC |
| Phase | : | Phase IIa |
| Study Location | : | Hong Kong |
| Status | : |
|
| Protocol No. | : | BCT-100-004 |
| Study | : | A study of the safety and efficacy of recombinant human arginase 1 (PEG-BCT-100) combined with capecitabine and oxaliplatin in patients with locally advanced or metastatic hepatocellular carcinoma |
| Condition | : | HCC |
| Phase | : | Phase II |
| Study Location | : | Hong Kong |
| Status | : |
|
| Protocol No. | : | BCT-100-005 |
| Study | : | Recombinant human arginase 1 (rhArg1) in patients with advanced, arginine auxotrophic solid tumors: dose escalation, safety and PK/PD |
| Condition | : | HCC, melanoma, renal cell carcinoma and prostate adenocarcinoma |
| Phase | : | Phase I |
| Study Location | : | USA |
| Status | : |  Ongoing |
| Protocol No. | : | BCT-100-006 |
| Study | : | A phase II trial of PEG-BCT-100 as the second-line therapy following sorafenib in patients with advanced hepatocellular carcinoma |
| Condition | : | HCC |
| Phase | : | Phase II |
| Study Location | : | Hong Kong, The Chinese University of Hong Kong |
| Status | : |
|
| Protocol No. | : | BCT-100-007 |
| Study | : | A Phase II Open-label Study of the Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients with Relapsed or Refractory Acute Myeloid Leukemia |
| Condition | : | AML |
| Phase | : | Phase II |
| Study Location | : | Hong Kong |
| Status | : | Prematurely terminated due to low recruitment rate |
| Protocol No. | : | LI-1 |
| Study | : | Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI-1) Trial Trial: Multicentre phase II/III interventional study |
| Condition | : | AML |
| Phase | : | Phase II |
| Study Location | : | UK |
| Status | : | Ongoing |
| Protocol No. | : | PARC |
| Study | : | A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults |
| Condition | : | Pediatric AML, ALL, NB, high grade glioma, sarcomas |
| Phase | : | Phase I/II |
| Study Location | : | Multinational (UK, Ireland and Australia) |
| Status | : | Ongoing |
